
Sign up to save your podcasts
Or


Originally Published as The Niche Podcast
Vaccines are here, capitalizing on capital with IPOs, and Gilead targets Hepatitis D.
Sponsors
https://www.thescopemethod.com
Story References
https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19
https://www.abcellera.com/news/2020-12-10-abcellera-announces-pricing-of-ipo
https://www.certara.com/pressrelease/certara-announces-pricing-of-its-upsized-initial-public-offering/
https://ir.4dmoleculartherapeutics.com/news-releases/news-release-details/4d-molecular-therapeutics-announces-upsized-pricing-initial
https://www.nanobiotix.com/wp-content/uploads/2020/12/PR-Pricing.pdf
https://www.gilead.com/news-and-press/press-room/press-releases/2020/12/gilead-sciences-to-acquire-myr-gmbh
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast
Everlywell expands at-home testing, Bayer and Atara strike deal, and Moderna heads to the FDA.
Sponsors
https://www.thescopemethod.com
Story References
https://www.prnewswire.com/news-releases/everlywell-announces-175-million-financing-to-expand-consumer-lab-testing-and-digital-health-offerings-301185355.html
https://media.bayer.com/baynews/baynews.nsf/id/Bayer-Atara-Biotherapeutics-enter-strategic-collaboration-generation-mesothelin-targeted-CAR-T?Open&parent=news-overview-category-search-en&ccm=020
https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-primary-efficacy-analysis-phase-3-cove-study
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast
This week, we take a thanksgiving break from the news cycle to bring you a special interview with a COVID survivor and healthcare worker, Trenton Barrick. He shares an inside perspective on the healthcare industry as well as his personal experience being hospitalized with COVID19.
Sponsors
https://www.thescopemethod.com
Trenton's Website
https://www.nmtworks.com/
Aphasia Choir
https://singaphasia.com/
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast
Pfizer submits to the FDA, how mRNA vaccines work, and Novartis drops a billion, but really only $50 million
Story References
https://www.biospace.com/article/pfizer-and-biontech-to-submit-covid-19-vaccine-to-fda-for-emergency-use-today/
https://www.biospace.com/article/releases/stoke-therapeutics-announces-pricing-of-97-5-million-public-offering/
https://www.novartis.com/news/media-releases/novartis-secures-exclusive-rights-potential-acute-respiratory-distress-syndrome-cell-therapy
Sponsors
https://www.thescopemethod.com
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast
COVID19 vaccine news, an app to stop nightmares, Agios targets Sickle Cell disease, and Silverback files to go public.
Sponsors
https://www.thescopemethod.com
Story References
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against
https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy
https://night-ware.com/news
https://investor.agios.com/news-releases/news-release-details/agios-announces-fda-orphan-drug-designation-granted-mitapivat-0
https://sec.report/Document/0001193125-20-290236/
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast
Aducanumab skeptics, Novo Nordisk and Merck make acquisitions, but first a market update.
Sponsors
https://www.thescopemethod.com
Story References
https://www.sciencemag.org/news/2020/11/biogen-s-alzheimer-s-drug-candidate-takes-beating-fda-advisers
https://www.merck.com/news/merck-announces-third-quarter-2020-financial-results/
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=33374
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast
Syneos Health acquires Synteract, Apellis strikes a billion-dollar deal, and clinical trial patient enrollment, but first a market update.
Sponsors
https://www.thescopemethod.com
Story References
https://www.investor.syneoshealth.com/news-releases/news-release-details/syneos-health-acquire-synteract-top-cro-provider-emerging
https://www.prnewswire.com/news-releases/new-greenphire-data-indicates-clinical-trial-industrys-swift-rebound-patient-enrollment-reaches-pre-pandemic-levels-301159557.html?tc=eml_cleartime
https://investors.apellis.com/news-releases/news-release-details/apellis-and-sobi-enter-collaboration-global-co-development-and
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast
This week, siteless with vision, IQVIA back on track, 36%, convalescent plasma, and Remdesivir approved.
Sponsors
https://www.thescopemethod.com
Story References
https://www.businesswire.com/news/home/20201020005645/en/LabCorp-Transforms-the-Clinical-Trial-Experience-And-Streamlines-the-Drug-Development-Process
https://www.businesswire.com/news/home/20201020005345/en/IQVIA-Reports-Third-Quarter-2020-Results-Raises-Full-Year-2020-Guidance-and-Provides-2021-Outlook
https://www.prnewswire.com/news-releases/thermo-fisher-scientific-reports-third-quarter-2020-results-301156312.html
https://www.bmj.com/content/371/bmj.m3939
https://www.nejm.org/doi/full/10.1056/NEJMoa2007764
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast
Failures in sickle-cell therapy, CRO mergers in Asia, Praxis IPO, and wasp venom.
Sponsors
https://www.thescopemethod.com
Story References
https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-announces-phase-2-strong-scd-study-results-patients
https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-announces-positive-data-iw-6463-cns-translational
https://novotech-cro.com/news/asia-pacific-has-record-year-clinical-trials-according-novotech
https://investors.praxismedicines.com/press-releases
https://www.pnas.org/content/early/2020/10/07/2012379117
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
Originally Published as The Niche Podcast
Nobel prizes, clinical trials for tinnitus, Takeda’s billion-dollar deal, and the White House keeps science political
Sponsors
https://www.thescopemethod.com
Story References
https://www.nobelprize.org/prizes/chemistry/2020/summary/
https://stm.sciencemag.org/content/12/564/eabb2830
https://www.nytimes.com/2020/10/05/us/politics/coronavirus-vaccine-guidelines.html
https://www.businesswire.com/news/home/20201008005340/en/
Music by Luke Goodson
https://www.soundcloud.com/lukegoodson
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.
From the publisher's feed